A randomized, double-blind, phase II study of first-line FOLFOX plus bevacizumab with onartuzumab versus placebo in patients with metastatic colorectal cancer (mCRC).

作者:Bendell Johanna C; Hochster Howard S; Hart Lowell L; Firdaus Irfan; Mace Joseph Ronald; McFarlane Joshua Jemison; Kozloff Mark; Catenacci Daniel Virgil Thomas; Hsu Jessie J; Hack Stephen Paul; Shames David S; Phan See Chun; Cohn Allen Lee
来源:Gastrointestinal Cancers Symposium, 2015-01-15 to 2015-01-17.
  • 出版日期2015-1-20